TMCnet News

Research and Markets: Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Pipeline Review, H1 2015 - 39 Companies & 45 Drug Profiles
[July 21, 2015]

Research and Markets: Plaque Psoriasis (Psoriasis Vulgaris) Therapeutics Pipeline Review, H1 2015 - 39 Companies & 45 Drug Profiles


Research and Markets (http://www.researchandmarkets.com/research/2jfx56/plaque_psoriasis) has announced the addition of the "Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

  • Almirall, S.A.
  • Amgen Inc.
  • Avesthagen Limited
  • Avxxin AS
  • Biocon Limited
  • Biotie Therapies Corp.
  • Can-Fite BioPharma Ltd.
  • Celltrion, Inc.
  • Circassia Pharmaceuticals plc
  • Coherus BioSciences, Inc.
  • Creabilis SA
  • Delenex Therapeutics AG
  • Dermira Inc.
  • Epirus Biopharmaceuticals, Inc.
  • Forward Pharma A/S
  • Galectin Therapeutics, Inc.
  • Genor BioPharma Co., Ltd.
  • Idera Pharmaceuticals, Inc.
  • Invion Limited
  • Johnson & Johnson
  • Kadmon Corporation, LLC
  • Kineta, Inc.
  • Kyowa Hakko Kirin Co., Ltd.
  • LEO Pharma A/S
  • Lipidor AB
  • Mabion SA
  • Maruho Co., Ltd.
  • Momenta Pharmaceuticals, Inc.
  • Oncobiologics, Inc.
  • Pfizer Inc.
  • Promius Pharma, LLC
  • Protalix BioTherapeutics, Inc.
  • Provectus Biopharmaceuticals, Inc.
  • R-Tech Ueno, Ltd.
  • TetraLogic Pharmaceuticals



Drug Profiles

  • (betamethasone dipropionate + bexarotene)
  • (calcipotriene + betamethasone dipropionate)
  • (calcipotriene + betamethasone)
  • adalimumab biosimilar
  • AM-001
  • ASKP-1240
  • AVX (News - Alert)-001
  • betamethasone + maxacalcitol
  • bimekizumab
  • brodalumab
  • BTT-1023
  • calcipotriene
  • CF-101
  • CIR-001
  • CT-327
  • dalazatide
  • DFD-01
  • DFD-06
  • dimethyl fumarate
  • DLX-105
  • DRM-02
  • etanercept biosimilar
  • GK-664S
  • GR-MD-02
  • guselkumab
  • IDP-118
  • IMO-8400
  • infliximab biosimilar
  • INV-103
  • KD-025
  • LEO-32731
  • LP-0113
  • M-801801
  • MOL-4239
  • MOL-4249

For more information visit http://www.researchandmarkets.com/research/2jfx56/plaque_psoriasis



[ Back To TMCnet.com's Homepage ]